Welcome to the International Society for Vaccines
Dr. Manon M.J. Cox, MBA founded NextWaveBio early 2018 initially providing scientific and strategic direction to various biopharmaceutical companies. NextWaveBio’s mission is to bridge the gap between preclinical and clinical development by offering infrastructure and education around quality systems required for clinical development and manufacturing. Prior to that she led the development of Flublok®, the only FDA approved recombinant influenza vaccine at Protein Sciences Corporation where she served as President and Chief Executive Officer since April 2010 and Director since 2008. She joined Protein Sciences in 1998 as Director of Business Development and became Chief Operating Officer in 2003.
Previously she was with Gist-brocades, a large Dutch company specialized in fermentation, where she held various management positions, most recently in New Business Development and before that in Production and Research and Development. Prior to joining Gist-brocades, she worked as a Molecular Biologist on the development of a PCR screening test for cervical cancer at the University of Amsterdam.
She serves on the Board of Directors of Vaxxas, the Netherland-America Foundation including its Education Committee, the International Society of Vaccines, and various Scientific Advisory Boards in the vaccine development space.
Dr. Cox has received many honors and awards recognizing her stature as a leader in innovation and influenza, including in 2014 receiving a Doctorate in Humane Letters honoris causa from St. Joseph University and the Woman of Innovation award from the Connecticut Technology Council and was elected fellow in the International Society of Vaccines in 2015. Dr. Cox holds a Doctorate from the University of Wageningen, received her MBA with distinction from the University of Nyenrode and the University of Rochester, NY and holds a Doctorandus degree in Molecular Biology, Genetics and Biochemistry from the University of Nijmegen, The Netherlands.